NCT06790823View on ClinicalTrials.gov

Effect of Probiotic Supplement on Improvement of Depressive Symptoms in Patients With Substance-Induced Depressive Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

April 12, 2023

Study Completion Date

April 12, 2023

Conditions
Depressive DisorderDepressive Disorder, Major Depressive Disorder
Interventions
DRUG

The probiotic supplement (Moodamin capsuls)

The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively.Excipients include xylitol, maltodextrin, plum flavor, and malic acid.

DRUG

Placebo

The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively. Excipients include xylitol, maltodextrin, plum flavor, and malic acid. A placebo product used for the control group was made up of excipients only.

Trial Locations (1)

71356-44144

Shiraz University of Medical Sciences, Shiraz, Iran, Shiraz

All Listed Sponsors
lead

Shiraz University of Medical Sciences

OTHER